What is the total authorization for Hinge Health's share repurchase program?

As of July 29, 2026, the total aggregate authorization is $496.5 million. This comprises the original $250 million authorized on November 10, 2025, plus the $300 million increase approved on July 29, 2026.

How much has Hinge Health repurchased to date under the program?

As of July 29, 2026, Hinge Health had repurchased $196.5 million of Class A common stock under the original $250 million authorization. In addition, the company repurchased $131.5 million during the six months ended June 30, 2026, reflecting active execution of the program.

What methods can Hinge Health use to repurchase shares?

The company may repurchase shares in the open market in compliance with Rule 10b-18, through Rule 10b5-1 trading plans, or in privately negotiated transactions. The timing, amount, price, and manner of repurchases are determined at management's discretion based on business conditions, stock price, and regulatory requirements.

How does Hinge Health plan to fund the repurchases?

The company expects to fund repurchases with existing cash and cash equivalents and cash generated from ongoing operations. As of June 30, 2026, Hinge Health had $475.6 million in cash, cash equivalents, and marketable securities.

HNGE 8-K Filed 2026-08-04 Amendment

Hinge Health board approves $300M increase to share repurchase program

Second authorization boost brings total to $496.5M; company reports 53% revenue growth and strong free cash flow

Remaining$300M

MechanismRule 10b-18 open-market purcha

What the filing says

Hinge Health's board of directors approved a $300 million increase to its share repurchase program on July 29, 2026, bringing the total aggregate authorization to $496.5 million. The company had previously authorized a $250 million program in November 2025, under which it repurchased $196.5 million of Class A common stock by July 29, 2026.

Repurchases under the program may be executed in the open market, in privately negotiated transactions, or by other methods, with amount, manner, price, and timing determined at the company's discretion. Open market repurchases will be structured in accordance with Rule 10b-18 under the Securities Exchange Act of 1934. The company may also enter into Rule 10b5-1 plans to facilitate repurchases. The program has no expiration date and may be modified, suspended, or terminated at any time by the board.

The timing of the authorization coincides with Hinge Health's second-quarter 2026 results announcement, in which the company reported revenue of $213 million, up 53% year-over-year, and free cash flow of $100 million, up 3x year-over-year. The company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.

On July 29, 2026, our board of directors approved an increase to the program, resulting in $300.0 million of our Class A common stock available for future repurchase, for a total aggregate amount authorized under the program of $496.5 million as of such date. — Hinge Health, Inc. 8-K filing · View on SEC EDGAR →

What this means

The $300 million authorization increase reflects Hinge Health's strong cash generation and operational performance. In the six months ended June 30, 2026, the company repurchased $131.5 million in Class A common stock and generated $141 million in free cash flow. The amendment expands the total program to $496.5 million, giving the board flexibility to return capital while maintaining balance-sheet strength (cash and securities totaled $475.6 million as of June 30, 2026). This capital allocation signals management confidence in the company's growth trajectory and valuation.

Frequently asked questions

What is the total authorization for Hinge Health's share repurchase program?: As of July 29, 2026, the total aggregate authorization is $496.5 million. This comprises the original $250 million authorized on November 10, 2025, plus the $300 million increase approved on July 29, 2026.
How much has Hinge Health repurchased to date under the program?: As of July 29, 2026, Hinge Health had repurchased $196.5 million of Class A common stock under the original $250 million authorization. In addition, the company repurchased $131.5 million during the six months ended June 30, 2026, reflecting active execution of the program.
What methods can Hinge Health use to repurchase shares?: The company may repurchase shares in the open market in compliance with Rule 10b-18, through Rule 10b5-1 trading plans, or in privately negotiated transactions. The timing, amount, price, and manner of repurchases are determined at management's discretion based on business conditions, stock price, and regulatory requirements.
Does the repurchase program have an expiration date?: No, the program has no expiration date and may be modified, suspended, or terminated at any time at the discretion of the board of directors.
How does Hinge Health plan to fund the repurchases?: The company expects to fund repurchases with existing cash and cash equivalents and cash generated from ongoing operations. As of June 30, 2026, Hinge Health had $475.6 million in cash, cash equivalents, and marketable securities.

amendment authorization rule-10b-18 rule-10b5-1 healthcare-tech mega-cap

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.